Title: An Animal Model to Study *Klebsiella pneumoniae* Gastro-Intestinal Colonization and Host-to-Host Transmission

Authors: Taylor M. Young\(^1\), Andrew S. Bray\(^1\), Ravinder K. Nagpal\(^{1,2}\), David L. Caudell\(^3\), Hariom Yadav\(^{1,2}\), and M. Ammar Zafar\(^*\)

Affiliations:
\(^1\) Department of Microbiology and Immunology Wake Forest School of Medicine, Winston-Salem, NC, USA.
\(^2\) Department of Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC USA.
\(^3\) Department of Pathology-Comparative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.

*Corresponding Author:*
M. Ammar Zafar
Wake Forest School of Medicine
Biotech Place, Suite 210, Room 2E-022
575 Patterson Ave
Winston-Salem, NC 27101
336-716-9083 - phone
mzafar@wakehealth.edu
Abstract.

An important yet poorly understood facet in the life cycle of a successful pathogen is the host-to-host transmission. Hospital-acquired infections (HAI) resulting from the transmission of drug-resistant pathogens affect hundreds of millions of patients worldwide. *Klebsiella pneumoniae* (*Kpn*), a gram-negative bacterium, is notorious for causing HAI, with many of these infections difficult to treat as *Kpn* has become multi-drug resistant. Epidemiological studies suggest that *Kpn* host-to-host transmission requires close contact and generally occurs through the fecal-oral route. Herein, we describe a murine model that can be utilized to study mucosal (oropharynx and gastrointestinal [GI]) colonization, shedding within feces, and transmission of *Kpn* through the fecal-oral route. Using an oral route of inoculation, and fecal shedding as a marker for GI colonization, we show that *Kpn* can asymptotically colonize the GI tract of immunocompetent mice, and modifies the host GI microbiota. Colonization density within the GI tract and levels of shedding in the feces differed among the clinical isolates tested. A hypervirulent *Kpn* isolate was able to translocate from the GI tract and cause hepatic infection that mimicked the route of human infection. Expression of the capsule was required for colonization and, in turn, robust shedding. Furthermore, *Kpn* carrier mice were able to transmit to uninfected cohabitating mice. Lastly, treatment with antibiotics led to changes in the host microbiota and development of a transient super-shedder phenotype, which enhanced transmission efficiency. Thus, this model can be used to determine the contribution of host and bacterial factors towards *Kpn* dissemination.
Introduction.

Host-to-host transmission of pathogens is the primary source of nosocomial infections, which are considered a serious threat to patient’s health and also a significant burden on the healthcare system (1, 2). Hospital-acquired infections (HAI) account for ~100,000 deaths in the United States alone (3). A leading cause of these hospital-acquired infections and multiple outbreaks in hospitals around the world is Klebsiella pneumoniae (K. pneumoniae; Kpn), a member of the Enterobacteriaceae family that frequently causes pneumonia, bacteremia, pyogenic liver abscesses, and urinary tract infections (4), with most of these infections generally occurring in immunocompromised patients. With the rampant use of antibiotics Kpn isolates have become extensively drug-resistant, and some are now even considered pan-drug resistant, making the infections they cause extremely difficult to treat (5-7). For this reason, WHO lists Klebsiella pneumoniae as a critical pathogen for which new antibiotics and other therapies are urgently required to address this growing healthcare problem (8, 9). Further exacerbating treatment of Kpn infections is the recent identification of isolates termed “hypervirulent K. pneumoniae” (hvKP) that can cause disease, such as community-acquired pyogenic liver abscesses in healthy individuals (10-12). Patients recovering from hvKP infections often suffer from post-infectious sequelae that can lead to loss of limb or vision (13-15). These strains, originally isolated in the Pacific Rim, have since disseminated worldwide (10).

In the natural environment, the initial mucosal sites of colonization tend to be the oropharynx and the gastrointestinal (GI) tract (16, 17). These colonization events are generally asymptomatic (18). However, under certain circumstances, Kpn can gain access to other sterile sites in the host and cause disease. Epidemiological data suggest that many patients in hospitals are Kpn carriers in the GI tract, with a correlation between Kpn carriage and subsequent disease from the same isolate (19-21). Besides patients, hospital personnel can also be asymptomatic carriers of Kpn, and these silent carriers act as a reservoir from which Kpn can manifest disease within the same host or act as a source of transmission to a new host (18, 22-24).

Colonization resistance provided by the host microbiota plays a critical role in blocking colonization by pathogens. However, the use of antibiotics diminishes the microbial diversity in the GI tract, which potentially allows Kpn to readily colonize a host. Studies also show that antibiotic treatment of mice predisposes them to a “supershedder” state where they shed resident gut pathogens at a higher number, which enhances host-to-host transmission (25, 26). It is,
however, unclear whether antibiotic treatment in a hospital setting contributes towards the increased transmission of drug-resistant Kpn.

Our understanding of the Klebsiella pneumoniae-associated disease-state comes mainly from animal models studying lung and urinary tract infection. While these studies have identified bacterial and host factors that contribute to Kpn virulence, there is very little mechanistic understanding of the gastrointestinal colonization and host-to-host transmission. Close contact, especially in a hospital setting, is thought to promote the spread of Kpn from an infected host to a naïve host. Transmission is thought to occur via the fecal-oral route, either through poor hygiene or contact with contaminated surfaces (fomites) (20, 22–24).

Here, we describe a murine model to allow for the study of Kpn GI colonization, shedding, and host-to-host transmission. Employing an oral route of Kpn inoculation in an inbred mouse population, we investigated K. pneumoniae gastric colonization and transmission. We demonstrate that Kpn can stably colonize the GI tract without treatment of antibiotics, and these mice stay persistently colonized and can transmit Kpn to cage-mates. Furthermore, antibiotic treatment of carrier mice induces gut dysbiosis and triggers a transient supershedder phenotype.

Materials and Methods.

Ethics Statement. This study was conducted according to the guidelines outlined by National Science Foundation animal welfare requirements and the Public Health Service Policy on Humane Care and Use of Laboratory Animals (27). Wake Forest Baptist Medical Center IACUC oversees the welfare, well-being, and proper care and use of all vertebrate animals. The approved-protocol number for this project is A18-160.

Bacterial growth conditions and strain construction. Strains used in the study are listed in Table 1. K. pneumoniae isolates were grown in Luria-Bertani (LB) Broth Lennox, with constant agitation at 37°C. For all mouse infections, an overnight culture of Kpn was spun down at ~27000 x g for 15 minutes, and the resulting pellet resuspended in similar volume of 1X Phosphate-Buffered Saline (PBS). To obtain desired density for mouse infections (10^6 CFU/100µl), the bacterial suspension in PBS was diluted into a 2% sucrose-PBS solution. Ten-fold serial dilutions were plated on selective media (LB-Agar with antibiotic) and incubated at
30°C overnight for quantitative culture. LB plates contained antibiotics to select for specific Kpn isolates. Antibiotics used for isolating various isolates included streptomycin (str, 500 µg/ml), chloramphenicol (50 µg/ml), ampicillin (25 µg/ml), apramycin (50 µg/ml), spectinomycin (30 µg/ml) and rifampin (30 µg/ml). Table 1 lists the resistance markers associated with the isolates used in this study.

The wzi gene codes for a conserved outer membrane protein involved in the attachment of capsular polysaccharide to the outer membrane. Sequence polymorphism in the wzi gene has been used to identify and characterize different isolates. Kpn AZ10 (wzi 372) an antibiotic sensitive isolate was made str-resistant as described, subsequently mouse GI passaged and named AZ99 (28, 29). To construct the fimH mutant in the appropriate genetic background, PCR was carried out using Q5 polymerase (NEB) with AZ10 genomic DNA as template, and primers fimH upstream (GGCGGTGATTAACGTCACCT) and fimH downstream (GATAGAGCAGCGTTTGCCAC), which give at least 500bp homology on either end of the transposon cassette. The PCR product was purified using the Qiagen MinElute kit. Lambda Red mutagenesis was carried out as described previously (30), and cells were recovered in Super Optimal Broth with Catabolite repression (SOC) media at 30°C with shaking overnight. Recovered bacteria were plated on selective LB agar containing chloramphenicol (50 µg/ml).

Single colonies were purified and the mutation was confirmed by PCR. Complement of the ΔwcaJ was constructed by cloning flanking upstream and downstream regions of wcaJ into conjugation plasmid pKAS46 (31) using primers LT016-GATCTGCGCGCGATCGATATCCGCGGTGAAATGCATGTGTC and LT019-GCGCCAGCTGCAGGCGGCCGCGCAGAGAGTTCACGGTTACG, and the plasmid electroporated in to E. coli S17-1λpir (32). Conjugation and subsequent selection of complemented strain was carried out as described (33).

To determine fim promoter orientation, PCR was carried out using either in vitro samples from LB broth, single colonies from LB plates, or in vivo samples (fecal pellets) from mice infected with Kpn. Broth culture was spun down as described above and resuspended in equal volume dH2O and boiled for 5 minutes. Also, a single colony was resuspended in 10 µl of dH2O and boiled for 5 minutes. DNA was isolated from fecal pellets (100 mg) using Quick-DNA™ Fecal/Soil Microbe Microprep (Zymo Research). 5 µl of sample was used in PCR with OneTaq polymerase (NEB) with primers Cas168 GGGACAGATACGCGTTTGAT and Cas169 GCCTAACTGACCGTTTTGA as described previously (34). Purified PCR product was digested with restriction enzyme HinFl (NEB) for 1 hour and resolved on 1.2% agarose gel. As established previously, the “off orientation” of the fim promoter results in product bands of 496bp and 321bp, whereas the “on orientation” results in bands of 605bp and 212bp (34).
Mouse Infections for Colonization and Shedding. Colonies of C57BL/6J (SPF) mice obtained from Jackson Laboratory (Bar Harbor, ME) were bred and maintained in a standard animal facility at Biotech Place, Wake Forest Baptist Medical Center. All animal work was done according to the guidelines provided by the American Association for Laboratory Animal Science (AALAS) (35) and with the approval of the Wake Forest Baptist Medical Center Institutional Animal Care and Use Committee (IACUC). 5-7 week-old mice were infected and monitored through the course of the experiments. Food and water was removed from mice ~4 hours prior to inoculation. *K. pneumonia* was grown overnight at 37°C with constant agitation, spun down in a microfuge at 21,000 x g for 20 minutes, resuspended and washed once with PBS, and finally diluted in 2% sucrose-PBS. Mice were fed ~10^6 CFU/100 µl of *K. pneumonia* in two 50 µl 2% sucrose-PBS doses an hour apart, from a pipette tip. Immediately afterwards, food was returned to mice. Similar protocol was followed for fasting mice and bacterial preparation for the gavage method of infection. Mice were gavaged with a 100 µl single dose of *Kpn* in 2% sucrose-PBS solution using a 20 gauge 1.5 inch single use feeding needle. For both methods of infections mouse scruffing, without any anesthesia was used.

To quantify daily bacterial shedding, mice were removed from their housing and placed into isolation containers. Fecal pellets (~0.02 g, approximately 2 pellets) were collected and placed into a 2 ml screwcap tube (Fisherbrand, 02-682-558) along with at least 2 glass beads (BioSpec, 11079127). Samples were diluted 1:10 in PBS (weight:volume). A Bead mill (Fisherbrand) was used to homogenize the fecal pellets (2.1 power setting, 1 min). Afterwards, the tubes were spun in a mini centrifuge (Thermo Scientific, MySpin 6) to pellet out larger debris. Ten-fold serial dilutions were plated from the supernatant on appropriate antibiotic plates and incubated overnight at 30°C. Bacterial shedding was calculated in CFUs per gram of feces. The limit of detection was 10^2 CFU/g. Each mouse was uniquely marked so that the fecal shedding of each individual mouse could be tracked for the duration of the experiment.

To trigger an antibiotic-dependent *Kpn* supershedder phenotype, mice were infected orally with a str-resistant *Kpn* as described above. Four to five days post-inoculation (p.i) mice were gavaged with streptomycin (5 mg/200 µl) either once or on three consecutive days, and daily shedding monitored post-antibiotic treatment. To determine effect of neomycin treatment before *Kpn* infection, mice were gavaged with a single dose (5 mg/200 µl) 24 hours before inoculation with the MKP103 a derivative of KPNIH1 isolate with a deletion of the KPC-3.
carbapenemase-encoding gene (36). Bacterial counts were enumerated from fecal pellets as described above. To determine the role of continuous antibiotic treatment on supershedder phenotype, the drinking water was replaced with water containing 1g/L ampicillin 24 hours before infection; mice were maintained on ampicillin-water for 10 day p.i. after which they were placed on regular water until the end of the experiment. Kpn fecal shedding was assessed up to 20 days post-infection, and quantified as described above.

For competition experiments, mice were infected with a 1:1 mixture of AZ94 and the mutant of interest. Fecal shedding of both strains was assessed as described above. Fecal homogenates were plated on both apramycin (50 µg/ml) and str (500 µg/ml) LB agar. The competitive index (CI) was calculated as described previously (37), using the following equation:

$$\log_{10} CI = \frac{\text{Mutant output / WT output}}{\text{Mutant input / WT input}}$$

A value of 0 would suggest that neither strain has an advantage. A value >1 would suggest that the mutant has competitive advantage, whereas a value <1 would indicate the WT has the advantage. Each CI experiment was carried multiple times (biological replicate ≥2) using mice housed separately and at different times.

To determine colonization density in the GI tract, ileum, cecum, and colon were removed under sterile conditions immediately following CO₂ (2 liters/min, 5 min) euthanasia of animals and subsequent cardiac puncture. The cecum, proximal colon, and a span of the terminal section of the ileum equal in length to the colon were removed from each animal. Organs were weighed and placed into individual 2 ml screwcap tubes (Fisherbrand, 02-682-558) with at least 2 glass beads (BioSpec Products, 11079127). Samples were diluted 1:10 in PBS (weight:volume) and were homogenized and plated as described above. The limit of detection was $10^2$ CFU/g.

To determine colonization density in the kidney, liver and spleen, organs were removed under sterile conditions immediately following euthanasia as described above. Organs were weighed and placed in 15 ml conical tubes. For kidney and liver equal weight to volume PBS was added, and samples were homogenized using PowerGen 700 (Power setting 2 for 30 seconds), whereas for spleen, ten times the volume of 1X PBS was added to the weight of the organ and homogenized as above. The samples were plated as described. The limit of detection of kidney and liver was 33 CFU/ml and for spleen $10^2$ CFU/ml.
Oropharyngeal lavage was carried out with 200 µl of sterile PBS from a gavage needle inserted into the esophagus. The esophagus was exposed and cut transversely. A gavage needle, attached to a prefilled insulin syringe (BD) with 1X PBS was then inserted into the cut esophagus, and PBS collected from the mouth. The collected lavage was serially diluted and plated on appropriate antibiotic plates and incubated overnight at 30°C. The limit of detection for oral lavage was 33 CFU/ml.

Transmission Studies. For 4:1 and 1:4 transmission experiments C57BL/6J index mice (n=1 or n=4) at 5-7 weeks of age are infected with Kpn as described above, and shedding is collected daily to determine colonization density of the GI tract. On day 4 p.i., contact mice (n=4 or n=1) were introduced to cages with the index mice. Fecal shedding of index and contact mice was collected and quantified for at least 6 days post-cohousing, for a total of 10 days for index mice and 6 days for contact mice. On day 10, the mice were euthanized as described above and the ileum, cecum, colon, and oral lavages of all mice were processed as described above to determine colonization density of Kpn.

In 1:4 transmission experiments, in which the administration of a single dose of antibiotic was assessed, index mice were infected with a str-resistant Kpn and fecal shedding of Kpn was quantified for 4 days p.i. On day 5 p.i., index mice were treated with streptomycin (5 mg/200 µl) via gavage and then co-housed with contact mice. Fecal shedding was collected daily from index and contact mice. In a continuous antibiotic challenge transmission study, an index mouse was put on water containing ampicillin (1 g/L) 24 hours before infection. The contact mice were placed on water containing ampicillin (1 g/L) 24 hours before introduction of the index mouse. Once co-housed, daily shedding was collected from both index and contact mice to determine if any transmission events occurred.

To confirm that host-to-host transmission events occur through the fecal oral route, a metabolic cage (Tecniplast Cat. # 3700M022) was used. Kpn infections were carried out as described above. 4 days post-infection, a contact mouse was introduced into the metabolic cage and fecal shedding collected from both index and contact mice to determine transmission frequency. The metabolic cage’s metal wire floor allows for fecal pellets and urine to fall through, separated through a special funnel and collect at the bottom. Therefore, the cage eliminates the ability of the mice to access fecal pellets for consumptions (coprophagia). For
each transmission study, \( n \geq 3 \) biologically independent experiments were carried out. End point colonization of the lower GI tract (ileum, cecum, colon and or fecal shedding) was considered as a positive transmission event.

**Histology.** Mice were infected with either PBS (vehicle-only control) or the KPPR1S isolate. A subset of \( Kpn \)-infected mice were gavaged with streptomycin (single treatment; 5 mg/200 \( \mu \)l) to induce the super-shredder state at 5 days p.i. As a positive control, mice were put on 3% w/v Dextran Sodium Sulfate (DSS) molecular weight 50,000 in their drinking water ad libitum for 7 days. All the mice were euthanized at day 7 post initial treatment or infection. 2.5 cm of colon immediately distal to the cecum was collected, washed with 1x PBS, and prepared using the Swiss roll method. Afterwards the sample was preserved in 1:10 Formalin (Fisherbrand, 305-510), and after 24 hours transferred to 70% ethanol. The samples were embedded in paraffin before being sectioned, mounted, and stained with hematoxylin and eosin (H & E). The resulting slides were scored by the Wake Forest Baptist Medical Center Pathology department.

Liver was collected under sterile conditions from either mock infected mice or from orally infected mice with hvKP1, and in extremis. Liver samples were cut in to sections about 6.5mm, and placed in 10% formalin (10 parts formalin to 1 part tissue). After 24-48 hours the samples were transferred to 70% Ethanol and stored at 4°C till they were further processed for H & E and Gram staining, with scoring carried out as described above.

**Fecal microbiome Analysis.** Fecal microbiome was examined according to previously described methods (38–40). Briefly, genomic DNA from 200 mg feces was extracted using MoBio Powerfecoal DNA kit (Qiagen, Valencia, CA) per manufacturer’s instructions. Amplicon PCR of the V4 hypervariable region of the 16S rDNA gene was performed using the universal primers 515F (barcoded) and 806R according to the Earth Microbiome Project protocol (PMID: 22402401). The amplicons were purified using AMPure® magnetic beads (Agencourt), and the products quantified with Qubit-3 fluorimeter (Invitrogen). The final amplicon library was generated as previously described (41). Equimolar pooled library was sequenced on an Illumina MiSeq platform using 2x300bp reagent kit (Miseq reagent kit v3; Illumina Inc.) for paired-end sequencing. The sequencing quality control was done with on-board Miseq Control Software and Miseq Reporter (Illumina Inc.) and the obtained sequences were de-multiplexed, quality-filtered,
clustered and analyzed using QIIME software package (38, 39, 42, 43). Taxonomy classification was performed within QIIME based on 97% sequence similarity to the Greengenes database (42). Alpha-diversity and bacterial proportions were compared using Kruskal-Wallis test followed by pair-wise Mann-Whitney test. Linear discriminatory analysis (LDA) effect size (LEfSe) was applied to identify discriminative features (unique bacterial taxa) that drive differences at different time-points or in different groups (44). Hierarchical clustering and heat-maps depicting the patterns of abundance were constructed within ‘R’ statistical software package (version 3.6.0; https://www.r-project.org/) using the ‘heatmap.2’ and “ggplots” packages.

**Statistical analysis.** All statistical analyses were performed using GraphPad Prism 8.0 (GraphPad Software, Inc., San Diego, CA). Unless otherwise specified, differences were determined using the Mann-Whitney U test (comparing two groups) or the Kruskal-Wallis test with Dunn’s post-analysis (comparing multiple groups).

**Results.**

**Establishing *Klebsiella pneumoniae* colonization in the murine intestinal tract.** We sought to establish a GI model of *Klebsiella pneumoniae* colonization that would mimic natural colonization in a host. Because of the difficulty in establishing Kpn GI colonization through gavage treatment, previous studies used antibiotic pre-treatment to disrupt the host microbiota and allow for Kpn colonization via the gavage method (45-47). We first tested the ability of Kpn to colonize the GI tract by giving adult mice doses ranging from $10^5$-$10^9$ CFU/100µl, without antibiotic treatment so as not to disrupt the host microbiota (Fig. 1A). However instead of a gavage treatment, mice were infected orally by pipette feeding to simulate the natural route of infection (48). We used a Kpn clinical isolate KPPR1S that has been used extensively to model Kpn-associated disease-state in mice. The streptomycin- and rifampin-resistance of KPPR1S allowed us to enumerate the bacteria in the fecal pellets on selective plates. As observed in Fig. 1B-C, Kpn colonized the GI tract and was shed robustly in the feces of mice with doses above $10^5$ CFU. A dose $<10^5$ CFU did not result in the establishment of colonization (Threshold for detection 100 CFU), suggesting a minimum dose of $10^5$ is required (Data not shown). Based upon these results, we chose $10^6$ CFU, as the minimum dose required to
establish *Kpn* colonization. Based on our preliminary studies that suggest poor *Kpn* fecal shedding correlates with reduced GI colonization, we used daily fecal shedding as a substitute for colonization density in the GI tract. Next, we determined how long *Kpn* colonizes the mouse GI tract. We followed *Kpn* shedding in feces of infected mice for either 15 or 30 days p.i and observed that *Kpn* was shed at similar levels throughout the study (Fig. 1D-E). Furthermore, our results showed that *Kpn* colonizes the mucosal surface of the oropharynx (Fig. 1F). Taken together, our data suggest that, when introduced by the oral route, *Kpn* colonizes the mucosal surface of the oropharynx, can establish and persist in the GI tract, and is shed robustly in the feces.

A hallmark of *K. pneumoniae* isolates is their genetic heterogeneity, which affects their ability in causing disease (49). Thus, we determined whether *Kpn* genetic plasticity also contributes to GI colonization. We tested the ability of a set of genetically diverse clinical *Kpn* isolates to colonize the GI tract of mice. For analysis we chose MKP103 a derivative of KPNIH1, which was the cause of an outbreak at NIH Clinical Center, hvKP1, a hypervirulent human isolate, and AZ99, a human fecal isolate. All three strains showed varying colonization density of the murine GI tract, with the hvKP1 shedding at a similar level to KPPR1S (Fig. 2A). Surprisingly, the MKP103 isolate colonized poorly, with mice generally clearing it from their GI tract by day 5 p.i. As observed through fecal shedding, the human fecal isolate AZ99 consistently colonized the GI tract albeit at a lower density in comparison to KPPR1S. Moreover, mice colonized with hvKP1 had a high mortality rate (Fig. 2C). Hypervirulent isolates are notorious for causing pyogenic liver abscesses (PLA) (11). As shown in Fig. 2D mice that succumbed after oral inoculation with the hvKP1 isolate, were colonized at a high density in the liver, kidney and spleen with the same isolate. Moreover, these mice appeared to have developed liver abscesses (Fig. 3A), which H&E and Gram staining confirmed to contain necrotic tissue, inflammatory cells, and gram negative bacteria (Fig. 3B-D). Development of liver abscess was a common outcome for mice infected with the hvKP1 isolate. Thus, our model mimics human disease dynamics, where a hypervirulent isolate (hvKP1) is able to translocate from the GI tract to other sterile sites, and cause the development of the disease state.

**Antibiotic treatment leads to the development of the *Kpn* supershedder phenotype.** Given that the fecal-oral route of transmission in a hospital setting is considered a significant cause of
nosocomial infections (50, 51) it was surprising that the MKP103 isolate failed to colonize the GI tract of mice (Fig. 2A). However, as many of the patients that acquired MKP103 in the GI tract were on antibiotics (20), we considered whether the use of antibiotics would affect the ability of this isolate to colonize the GI tract. Moreover, high use of antibiotics in a health-care setting correlates with *Klebsiella pneumoniae* infections (20). Therefore mice were gavaged with neomycin to reduce the colonization resistance by the host GI microbiota, and then infected with MKP103 to determine whether antibiotic treatment positively affected its ability to colonize. As shown in Fig. 2B antibiotic pre-treatment of mice allowed MKP103 to colonize and persist within the infected host GI tract up to 15 days post-infection.

Our results show that antibiotic treatment allows *Kpn* isolate (MKP103) that colonizes poorly to establish itself in the GI tract. However, whether antibiotic treatment affects colonization density of isolates that colonize robustly without requiring antibiotic treatment remains unknown. We determined whether treatment with antibiotics would lead to the development of a supershedder phenotype, in which an infected host sheds the pathogen at a much higher number than other infected host. This phenomenon has been observed in the natural setting and is considered a major source of host-to-host transmission (52). Murine models have been used to characterize this phenotype, where >10^8 CFU/g (supershedder [SS] threshold) of the indicated pathogen in the feces is generally considered as the threshold for the supershedder phenotype (SS phenotype) (25, 26). Using the KPPR1S isolate, as it consistently colonized mice at a high density without antibiotic treatment, we assessed fecal shedding of *Kpn* for 10-12 days p.i. after either a single streptomycin treatment or three consecutive days of streptomycin treatment. We found that antibiotic treatment triggered a temporary supershedder phenotype (Fig. 4A-B), whereas, no such phenotype was observed with the vehicle only control (PBS) (Fig. S1). A second treatment of antibiotics, after mice had returned to baseline levels of *Kpn* shedding from the first antibiotic treatment, caused the development of another transient supershedder phenotype (Fig. 4C).

In a clinical setting, immunocompromised patients tend to be on continuous antibiotic treatment; therefore, we determined the effect of daily antibiotic treatment on *Kpn* shedding. We supplemented the drinking water of mice with ampicillin 24 hours before *Kpn* inoculation and continued for 10 days p.i. As *Kpn* is intrinsically resistant to ampicillin, the mice infected with MKP103 isolate displayed the *Kpn* supershedder phenotype (Fig. 4D). After removal of
antibiotic pressure, the mice displayed the high shedding phenotype for multiple days. Taken together, our data suggest that, as a consequence of antibiotic treatment, *Kpn* can develop a supershedder phenotype and the length of this phenotype is dependent upon the duration of the antibiotic treatment.

**Antibiotic treatment leads to the disruption of host-microbiota that correlates with the supershedder phenotype.** Next, we determined whether *Kpn* infection or antibiotic treatment induced supershedder phenotype is a result of the displacement of the host microbiota. To provide insight into the *Kpn* carrier state and the supershedder phenotype, we carried out a 16S analysis to determine the host intestinal microbiota changes that occurred during infection and as a consequence of antibiotic treatment (Fig. 5A). For a detailed 16S analysis, we isolated DNA from fecal samples collected at six different time points from *Kpn* infected mice (n=4). Fecal pellets were collected pre-inoculation to determine the baseline of the host GI microbiota. Samples were collected on days 7, 9 and 11 post-antibiotic treatment to determine changes in the host microbiota. At days 3 and 5 p.i, we were unable to detect *Kpn* 16S rRNA gene sequences, even though it shed at $10^6$ CFU / Gram of fecal sample. This result suggests that *Kpn* comprises only a minor component of the host intestinal microbiota. The main component of a diverse microbial community of the host intestine included *Bacteroidetes* (*Bacteroidales* [S24-7]) and *Firmicutes* (*Clostridiales*) (Fig. 5C; Table. S1), which are considered to be a typical profile for stable mammalian intestinal microbiota.

A single treatment with str led to dramatic changes in the intestinal microbiota. As detailed in Fig. 5B, there was a statistically significant decline in the total species richness, especially in S24-7, with a concurrent increase in *Erwinia* and *Bacteroides*. As illustrated in Fig. 5C, we only observed *Kpn*-specific 16s rRNA gene sequences during the antibiotic-induced supershedder phenotype. A decrease in *Kpn* shedding levels correlated with an increase in S24-7 and other major components of the host microbiota, and a loss of detection of *Kpn* specific 16s rRNA sequences. Thus, antibiotic treatment leads to a disruption of host-microbiota that correlates with the development of temporary supershedder phenotype. Moreover, disruption of the host microbiota with antibiotics is associated with reduced microbial richness, which recovers three days post-antibiotic exposure.
Klebsiella pneumoniae factors contributing to shedding and colonization. To examine the contribution of known virulence determinants of Kpn, we tested shedding and colonization of the previously described capsule (cps)-deficient mutant (ΔmanC) of the strain KPPR1S. As is evident from Fig. 6A, over the course of 15 days of infection, the ΔmanC mutant shed and also colonized poorly (Fig. S2) in comparison to the parental wild-type (WT) strain. To provide further evidence of the role of CPS in GI colonization, we also tested a wcaJ deletion mutant (53), which codes for a glycosyltransferase involved in initial steps of CPS production. Similar to ΔmanC, the ΔwcaJ mutant over the course of the 15 days shed poorly (Fig. 6B). Furthermore, when ΔwcaJ was chromosomally complemented (wcaJ+), it behaved as the parental WT strain (Fig. 6B; Fig. S2), suggesting that the colonization defect is specific to CPS.

Bacteria can form biofilm like structures in the GI tract (54). We hypothesized that a coinfection with WT Kpn and the ΔmanC strain would form a mixed population (intraspecies) biofilm in the GI tract, helping compensate for the capsule deficiency of the ΔmanC strain. However, coinfected mice still shed the ΔmanC strain poorly compared to the parental strain (Fig. 6C). These observations suggest that capsular polysaccharide of Kpn is essential for robust GI colonization and eventual fecal shedding.

Next, as the type 1 fimbriae of Kpn is considered essential for colonization of the host urinary tract, we determined its role in GI colonization (34). The KPPR1S fim locus promoter is under phase variable control, which was observed to be in the off position under both in vitro (broth culture) and in vivo (fecal pellets) (data not shown). To determine the requirement of type 1 fimbriae of KPPR1S in GI colonization, a deletion mutant of fimH that encodes the type 1 fimbriae tip adhesin, required for proper interaction with the host epithelial layer (55) was constructed. As is evident from Fig. 6D-E, even though mice infected with the fimH- mutant had reduced median shedding, it was not significantly lower than the WT strain. Lastly, we determined whether these mutants also contribute towards colonization of the mucosal surface of the oropharynx. Fig. 6F shows, capsule was essential for colonization of the oropharyngeal space, whereas type 1 fimbriae was dispensable. Overall our data indicate that Kpn capsular polysaccharide plays a critical role in GI colonization. In contrast, Kpn type1 fimbriae appears to be nonessential for gut colonization.
Klebsiella pneumoniae transmission occurs through the fecal-oral route. Transmission of enteric pathogens generally occurs through the fecal-oral route, and host-to-host transmission in a hospital setting is a major source of infection (20, 50). Thus, we determined whether Kpn host-to-host transmission events could be observed in our animal model. Initially, we housed one uninfected mouse (contact) with four infected mice (index). Fecal pellets were collected to enumerate colonization density and whether transmission from index to contact mice occurred. We observed 100% transmission efficiency with a ratio of 4:1, with transmission occurring within 24 hours of cohousing the animals in all of our experiments (Fig. 7A and C). Since transmission efficiency is high with a ratio of 4:1, we decided to determine Kpn transmission dynamics with one index mouse cohoused with four contact mice. With a ratio of 1:4 reduced transmission efficiency (~31%) was observed, suggesting that not enough Kpn shedding events occurred for all uninfected mice to become colonized (Fig. 7B-C). However, in all of the 1:4 ratio transmission studies (n=4), we observed at least one successful transmission event in each of the experiments.

Next, to mimic conditions prevalent in a hospital, where patients tend to be on antibiotics, we investigated the effects of antibiotic treatment on Kpn transmission dynamics. A single antibiotic treatment to the index mouse cohoused with four contact mouse led to >90% transmission, suggesting that high Kpn shedding in the fecal pellets can overcome colonization resistance of the contact mice (Fig. 7C). Lastly, we tested the effect of antibiotics on both index and contact mice by adding antibiotics in their drinking water. An index mouse was infected with MKP103 and was housed separately for several days before being introduced to four contact mice already on antibiotics. We observed 100% transmission efficiency when both index and contact mice were on daily antibiotics. Moreover, as all the mice in the cage were on antibiotics, they all developed the supershedder phenotype (Fig. S3A). Our results provide insight into the high transmissibility of Kpn in hospitals where there is high antibiotic usage.

We hypothesize that Kpn transmission occurs through the fecal-oral route, based upon transmission models of other enteric pathogens and the coprophagic nature of mice. However, as Kpn colonizes both the oral cavity and the GI tract, we determined whether host-to-host transmission of Kpn is due to the coprophagic action of mice or by contact with infected oral secretions. Mice were housed in a metabolic cage, where they do not have access to their fecal pellets. At a 4:1 ratio of the index to contact mice, no transmission events were detected between
the infected and the uninfected mice during the 10-day experiment, suggesting that in our animal model, host-to-host transmission requires the contact with fecal matter (Fig. 7C). Lastly, the infected mice in the metabolic cage shed Kpn robustly when compared to infected mice housed in regular cages, suggesting persistent colonization that did not require re-seeding through the consumption of infected fecal pellets (Fig. S3B).

**Discussion**

The genetic heterogeneity of *Klebsiella pneumoniae* allows this pathogen to colonize a variety of host mucosal surfaces, which can dramatically impact the clinical outcome. *Klebsiella pneumoniae* disease manifestations in the respiratory and urinary tract have been extensively modeled in animals (4). However, the gastrointestinal mucosal surface, also colonized readily by *Kpn* has not been the focus of many scientific studies (56, 57). In this report, we describe a murine model of oral infection of *K. pneumoniae* to study GI colonization and host-to-host transmission. We demonstrate for the first time that Kpn can stably colonize the GI tract of immunocompetent mice without disrupting the host-microbiota - a key strength of our model. Secondly, a host colonized persistently with a pathogen is considered a significant reservoir for new infections, and our animal model of *Kpn* GI colonization replicates this phenotype, indicating it is a useful tool to study within-host events and host-to-host transmission. Third, we observed variability in the ability to colonize the GI tract and to cause invasive disease between different *Kpn* isolates, suggesting *Kpn* genetic plasticity might be involved in the observed variability. Lastly, as many patients in a hospital setting tend to be on antibiotics, we were able to show experimentally for the first time that antibiotic treatment triggers the development of the supershedder phenotype in carrier mice, which promotes host-to-host transmission.

Previous studies used antibiotic treatment to reduce host colonization resistance by disrupting the resident microbiota to establish *Kpn* colonization (34, 45, 58). However, treatment with antibiotics reduces the ability to discern the role of bacterial factors that allow *Kpn* to overcome colonization resistance. Our model does not require the use of antibiotics to establish stable and persistent *Kpn* colonization, and therefore allows for the identification of bacterial and host factors that contribute to *Kpn* colonization and transmission. In our initial studies, we established that the route of infection is critical for stable colonization of *Kpn* in the GI tract. Oral gavage, a standard mode of infection for modeling enteric infections in murine models, only...
led to transient *Kpn* colonization in the GI tract (Fig. S4). However, by orally feeding a similar
dose allowed *Kpn* to colonize the GI tract and persist without disrupting the host microbiota. A
recent study by Atarashi *et al.* showed that *Kpn* colonizing the oral cavity of patients can seed the
GI tract (48). In our model of infection we also observed *Kpn* colonizing the murine oral cavity.
How oral feeding promotes robust *Kpn* colonization compared to the gavage method remains to
be determined. It is possible that the oral route provides a mechanism though which *Kpn* is
primed to colonize the GI tract. Future studies will aim to provide an understanding of *Kpn*
priming that promotes its colonization of the GI tract.

A hallmark of many GI pathogens is their ability to cause an acute host inflammatory
response. Multiple reports also suggest that *Kpn* might contribute towards gut dysbiosis and play
an active role in inducing host response (48, 59). However, epidemiological data also suggest
that *Kpn* can silently colonize healthy individuals (18). In our murine model, we were unable to
detect any acute signs of inflammation post-*Kpn* infection. Furthermore, unlike the *Salmonella*
serovar *Typhimurium* supershedder phenotype, the *Kpn* antibiotic-induced supershedder
phenotype was not associated with colitis (Fig. S5). Our data suggest that *Kpn* (KPPR1S isolate)
in the GI tract behaves in a manner that generally does not elicit an acute inflammatory response
and carriage is considered an asymptomatic event.

The role of major virulence factors of *Kpn*, including its capsular polysaccharide (CPS),
type 1 fimbriae, and others have been extensively examined under both *in vitro* and *in vivo*
conditions (4). However, data for the requirement of *Kpn* CPS in GI colonization appears
contradictory (45, 46, 60, 61). As those studies were undertaken in mice treated with antibiotics,
it is possible that the exact role of the bacterial factors is probably masked. Herein, using our
model, we show definitively that CPS of *Kpn* is an essential component required for efficient
colonization of both the upper (oropharynx) and lower (intestinal) GI tract. The role of the
capsule possibly pertains to protection against host-mediated clearance and interactions with
mucus (46, 62, 63).

We also tested the requirement of the *Kpn* type 1 fimbriae in GI colonization. Even
though the type 1 fimbriae is critical for colonization of the urinary tract, it appears to be
dispensable for GI colonization (34). However, with certain pathogenic *E. coli* isolates, type 1
fimbriae is required for colonization (64, 65). Furthermore, recent work by Jung *et al.* using
antibiotic-treated mice observed a defect in GI colonization with a *Kpn fimD* mutant that is
missing the usher constituent that facilitates assembly and eventual translocation of the pilus across the outer membrane (58). However, in our model we only observed a slight reduction in median shedding from mice infected with the fimH isogenic mutant compared to the WT strain, suggesting that the expression of the type 1 fimbriae of the KPPR1S isolate is dispensable for GI colonization. This result that the type 1 fimbriae of KPPR1S isolate does not contribute towards GI colonization was not unexpected, as we did not observe its expression under the conditions tested (Data not shown). However, type 1 fimbriae might play a role in GI colonization for isolates that do express the structure.

Our model also allows us, for the first time, to understand the transmission dynamics of *Klebsiella pneumoniae*. We observed transmission events between *Kpn*-infected and contact mice, suggesting that *Kpn* shedding in this model is high enough to permit transmission, albeit at a lower frequency. We also observed that the contact mice colonized at a lower density compared to the index mice, possibly because of the reduced *Kpn* dose in the fecal pellets. Thus, our data follows epidemiologic studies that suggest 5-25% carriage rates in the natural environment (19, 66). However, the treatment of either infected or contact mice with antibiotics led to a high host-to-host transmission frequency. A single dose of antibiotic treatment established a suppershedder phenotype in the index host, which was able to transmit to >90% of uninfected mice. It is suggested that 80% of the infections are due to 20% of infected individuals transmitting to uninfected hosts (known as the 80/20 rule) (67). Such individuals are termed as supershedders or superspreaders. However, we were unable to observe a *Kpn* suppershedder phenotype without disrupting the host microbiota, suggesting that in our animal model, *Kpn* transmission dynamics do not follow the 80/20 rule. Multiple studies on enteric pathogens show that antibiotic treatment causes a dysbiosis in the GI tract, reduces colonization resistance by the stable resident microbiota, and promotes the expansion of pathogens (25, 26). Our 16S analysis shows that the antibiotic-based suppershedder phenotype correlates with a reduction in microbial diversity. In contrast to *Salmonella* serovar *Typhimurium* and *Clostridium difficile* suppershedder phenotypes (25, 26), the *Kpn* suppershedder phenotype lasts for a shorter duration following a single antibiotic treatment. However, *Kpn* infected mice on continuous antibiotics shed at suppershedder levels, a condition we believe to be common in a hospital setting. Our data suggest that the development of the suppershedder phenotype is the main contributor to host-to-host transmission events in a hospital. The transmission frequency of *Kpn*...
pneumoniae has not been established in a hospital setting and may be higher or lower than the rates determined in our murine model. We believe that a setting with high antibiotic use increases the likelihood of Kpn outbreaks. Therefore, patients on antibiotics should be carefully monitored to determine if they are colonized with K. pneumoniae.

In conclusion, we have described a model that will be useful in understanding complex interactions between K. pneumoniae and the host immune system and the intestinal microbiota. The availability of an arrayed marked mutant library of Kpn (36) and several annotated Kpn genomes should allow for studies identifying bacterial factors that contribute towards Kpn colonization and transmission. Since a majority of Kpn nosocomial infections arise from GI colonization and fecal-oral route of transmission (20, 29), an understanding of the biology of Kpn gastrointestinal colonization and fecal-oral transmission would be valuable as it could serve as an ideal point of intervention.

Acknowledgements

We would like to thank Drs. Michael Bachman (University of Michigan), Alan Hauser (Northwestern University), Virginia Miller (UNC Chapel Hill), Thomas Russo (University of Buffalo-SUNY) and Jeffery N. Weiser (NYU School of Medicine) for the strains used in this study. We would also like to thank Logan Treat (UNC Chapel Hill) for construction of the wcaJ+ complement strain used in this study. Lastly, we are grateful to Drs. Phillip Hernandez (Boston University), Virginia Miller, Kimberly Walker (UNC Chapel Hill), Jeffrey N. Weiser and Tonia Zangari (NYU School of Medicine) for fruitful discussions in regards to the establishment of the model and the manuscript.

This study was funded by startup funds provided by Wake Forest Baptist Medical Center to M.A.Z. A.S.B was supported by NIAID training program in Immunology and Pathogenesis 5T32AI007401-28.
Figures:

Figure 1. *K. pneumoniae* colonizes the gastro-intestinal tract of mice. (A) A schematic representation of C57BL/6J mice orally infected with *K. pneumoniae* KPPR1S isolate (10⁵, 10⁶, 10⁸ and 10⁹ CFU) (n=4 mice in each group). (B-C) shows quantified daily shedding results and colonization density in the intestinal tract (ileum, cecum and colon) at day 7 post-inoculation from mice given different *Kpn* doses. (D-E) Fecal shedding data collected from mice given 10⁸ CFU of KPPR1S and followed for up to either 15 days or 30 days post-infection (n=9 mice in each group). (F) (i, ii) Colonization density of KPPR1S isolate in the oropharynx and lower GI tract of mice 15 days post-inoculation. Bars indicate the median values. L.O.D, limit of detection.

Figure 2. Differences among *K. pneumoniae* clinical isolates in fecal shedding levels and virulence. (A.) Mice were infected with the indicated *K. pneumoniae* isolate with daily shedding values shown (n≥5 mice for each isolate). Differences in total shedding over the course of infection (15 days) between different *Kpn* isolates determined using Kruskal-Wallis test. KPPR1S vs MKP103 ***, p < 0.001; KPPR1S vs hvKP1 n.s, not significant; KPPR1S vs AZ99 *. p < 0.05 (B.) Comparison between mice infected with *K. pneumoniae* strain MKP103 with or without pretreatment of antibiotic neomycin (5 mg/200 µl) (n≥7 mice in each group). Symbols represent shedding values obtained from a single mouse on a given day. The bar represents the median value. Dashed line represents the limit of detect (L.O.D). Mann-Whitney test used to determine the differences in fecal shedding. (C.) Survival of mice infected gastro-intestinally with *K. pneumoniae* isolate KPPR1S (n=10) or hvKP1 (n=10) over 15 days. An in extremis state or death was scored as non-survival. Log-rank (Mantel-Cox) test performed to determine statistical differences in survival. (D.) Bar graph showing median colonization density of hypervirulent isolate hvKP1 in the kidney, liver and spleen from mice that were initially infected orally. Each data point represents colonization density in a specific organ from a specific mouse. Organs were harvested from mice that displayed an in extremis state. Limit of detection of liver and kidney was 33 CFU/ml and 10⁷ CFU/ml for spleen. **, P <0.01 for KPPR1S compared to hvKP1. *, p < 0.05, **, p < 0.01, n.s, not significant. Differences in total shedding over the course of infection (15 days) between different *Kpn* isolates determined using Kruskal-Wallis test. KPPR1S vs MKP103 ***, p < 0.001; KPPR1S vs hvKP1 n.s, not significant; KPPR1S vs AZ99 *, p < 0.05.

Figure 3. Representative *K. pneumoniae* liver abscesses (Red Arrows) from mice that succumbed to infection from hvKP1 isolate that originally colonized their GI tract (A.). Liver tissue samples stained with hematoxylin and eosin staining. Shown here are liver tissue sample at 20X resolution from either uninfected mice (B.) showing normal heptocytes or from infected mice (C.) that contains a large region of coagulative and lytic necrosis with hepatocellular disassociation including central infiltrates of neutrophils (*) with few scattered mononuclear
inflammatory cells. The peripheral aspect of the lesion contains numerous lymphocytes, macrophages and new scattered neutrophils (arrows). (D) 100X oil immersion image of the boxed area from C showing Gram negative bacteria present within the necrotic liver tissue.

**Figure 4.** Antibiotic treatment of *K. pneumoniae* infected mice triggers the supershedder phenotype. Fecal shedding from individual mice (n=9) infected with *K. pneumoniae* KPPR1S given a single dose of streptomycin sulfate (5 mg/200 µl) (A.) or (n=4) given three treatments of streptomycin on consecutive days (B.), resulted in a rapid development of high shedding (>10⁸ CFU / Gram of feces) [Supershedder (SS) threshold] lasting for 3 days post antibiotic treatment. (C.) Streptomycin sulfate (5 mg/200 µl) treatment triggers the supershedder phenotype (> 10⁸ CFU/Gram of feces) in mice (n=4) infected with *Kpn*. A second treatment of Streptomycin sulfate (5 mg/200 µl) once mice have returned to basal *Kpn* shedding elicits a second transient supershedder state. (D.) High fecal shedding of *K. pneumoniae* isolate MKP103 from mice (n=6) given ampicillin (1g/Liter) in drinking water. Removal of antibiotic pressure begins an eventual shift to reduced fecal shedding (<10⁸ CFU/Gram of feces).

**Figure 5.** Antibiotic triggered supershedder phenotype correlates with reduced intestinal microbial diversity. (A.) Average fecal shedding of *K. pneumoniae* isolate KPPR1S by carrier mice (n=4) pre antibiotic treatment, and post single dose streptomycin treatment (5 mg/200 µl) that induces a transient supershedder phenotype. Error bars represent S.E.M. Dashed line represents the supershedder (SS) threshold. (B.) Intestinal microbiota changes in carrier mice from samples obtained on day 0 pre infection, days 3 and 5 post-inoculation, and days 7, 9 and 11 post-antibiotic treatment. DNA was isolated from fecal samples obtained from infected mice and 16s rRNA analysis carried out. Data is shown as Shannon diversity index with mean and Stdev values shown. Statistical differences calculated by Kruskal-Wallis test. (C.) Shift in microbial diversity determined from fecal samples collected on the days indicated above and shown as bar graph with percent relative abundance of major genera. Arrow shows identification of *Klebsiella pneumoniae* DNA at Day 7 post-infection. *, p value < 0.05, **, p < 0.01

**Figure 6.** The effect of *K. pneumoniae* virulence factors on fecal shedding and oropharyngeal colonization. (A-B.) Mice were infected orally with KPPR1S (WT), with capsule-deficient mutants (*AmanC, AwcaJ*) or the chromosomally complemented strain (*wcaJ*⁺), and fecal shedding collected on the days indicated (n≥10 for each group). Each symbol represents CFU obtained from a single mouse on a given day, with solid line representing median values. Mann-Whitney test used to determine the differences in fecal shedding between WT and *AmanC*. Kruskal-Wallis test used for comparing WT with *AwcaJ* and *wcaJ*⁺. No statistical differences were observed in shedding between WT and *wcaJ*⁺. (C.) Mice were infected orally with a 1:1 mixture of WT and the capsule-deficient mutant (*AmanC*) with fecal shedding collected on the days indicated (n≥10). The CI was determined as described in the Materials and Methods. Each symbol represents Log₁₀ CI value from an individual mouse on a given day. Solid line represents the median. Dashed line indicates a competitive index of 1, or a 1:1 ratio of mutant to WT. (D.) Mice were infected orally with WT or with an isogenic mutant (*fimH::cam; FimH⁻*), and fecal shedding collected on the days indicated (n≥10 for each group). (E.) Mice were infected orally
with a 1:1 mixture of WT and the mutant (FimH-) with fecal shedding collected on the days indicated. The CI was determined as mentioned in Materials and Methods (n≥10). (F.) The colonization density in the oropharynx for the WT isolate, the isogenic mutants and the complemented strain was determined 15 days post-infection with median values shown. For CI statistical differences determined by Wilcoxon signed rank test. Differences in oropharyngeal colonization determined using Kruskal-Wallis test. *, p < 0.05. **, p < 0.01. ***, p < 0.001, ***, p < 0.0001.

**Figure 7.** *K. pneumoniae* transmission between hosts with and without treatment of antibiotics. (A.) A representative of 4:1 ratio of index to contact transmission. Four naïve mice were infected orally with KPPR1S, and housed with one uninfected mouse. Fecal shedding was monitored daily from both the index and the contact mouse. (B.) A representative of 1:4 ratio of index to contact transmission. One naïve mouse was infected orally with KPPR1S, and housed with four uninfected mice and fecal shedding monitored daily (C.) Observed efficiency of *K. pneumoniae* transmission with different infected to uninfected ratios, effect of antibiotics, and transmission dynamics in a metabolic cage. Statistical differences calculated using two-tailed Fisher’s exact test. In all transmission studies, fecal colonization was observed within 24 hours. In 1:4 no treatment transmission studies (n=4), at least one successful transmission event was observed.
### Strains used in this study

| Strain | Description | Antibiotic Resistance | Reference or Source |
|--------|-------------|-----------------------|---------------------|
| AZ10   | *K. pneumoniae* stool isolate. ST 1322; wzi 372. | Amp<sup>R</sup> | (29) |
| AZ99   | Mouse passaged Streptomycin derivative of AZ10 | Amp<sup>R</sup>, Str<sup>R</sup> | This Study |
| AZ17   | KPPR1 serotype 2 *K. pneumoniae* isolate. Derivative of ATCC43816 | Rif<sup>R</sup> | (68) |
| AZ55   | KPPR1S; Str<sup>R</sup> derivative of KPPR1. | Rif<sup>R</sup>, Str<sup>R</sup> | (69) |
| AZ56   | ΔmanC (CPS-) mutant of KPPR1S. | Rif<sup>R</sup>, Str<sup>R</sup> | (33) |
| AZ70   | MKP103. A carbapenemase (KPC-3) deletion derivative of KPNIH1 | Amp<sup>R</sup> | (36) |
| AZ71   | hvKP1. Hypervirulent *K. pneumoniae* K-type 2 isolate. | Amp<sup>R</sup> | (70) |
| AZ94   | Apramycin cassette at *att::tn7* site derivative of KPPR1. | Apra<sup>R</sup>, Rif<sup>R</sup> | (71) |
| AZ63   | AZ55 with pKD46 plasmid for lambda red recombination. | Rif<sup>R</sup>, Str<sup>R</sup>, Spec<sup>R</sup> | This study |
| AZ101  | Arrayed Library, MKP103 with transposon element in *fimH:cam* | Cam<sup>R</sup> | (36) |
| AZ108  | Moved *fimH:cam* cassette from AZ101 into AZ63, and plasmid cured. | Rif<sup>R</sup>, Str<sup>R</sup>, Cam<sup>R</sup> | This Study |
| AZ124  | *AwcaJ* (CPS-) mutant of KPPR1S (AZ55) | Str<sup>R</sup> | (53) |
| AZ128  | *wcaJ* (chromosomal complemented) derivative of AZ124. | Str<sup>R</sup> | This Study |

a. Amp<sup>R</sup>, Ampicillin resistant; Apra<sup>R</sup>, Apramycin resistant; Rif<sup>R</sup>, Rifampin resistant; Str<sup>R</sup>, Streptomycin resistant; Spec<sup>R</sup>, Spectinomycin resistant; Cam<sup>R</sup>, Chloramphenicol resistant
Figure 1.

A. Oral Infection

B. Fecal Analysis (Days) Necropsy

C. Log of CFU / Gram of Feces

D. Days Post-Infection

E. Log of CFU / Gram of Sample

F. i.) Log of CFU / ml

Oropharynx

ii.) Log of CFU / Gram of Sample

Ileum Cecum Colon

Day 15 Post-Infection
Figure 2.

A. 

B. 

C. 

D. 

Days Post-Infection

Log$_{10}$ CFU / Gram of Feces

Log$_{10}$ CFU / Gram of Feces

Days Post-Infection

% Survival

Days Post-Infection

Log$_{10}$ CFU / Gram of Tissue

Kidney | Liver | Spleen

0.0064

KPPRS

hvKP1

MKP103

MKP103 (No Treatment)
Figure 3.
Figure 4.

A. Streptomycin Treatment

B. Streptomycin Treatment

C. ABX Treatment

D. ABX Treatment

Days Post-Infection
Figure 5.

A. 

B. 

C. 

Relative Abundance of Major Genera

- Others
- Klebsiella
- Peptostreptococcaceae
- Lactobacillus
- Ruminococcus
- Clostridiales
- Bacteroides
- Erwinia
- S24-7

Days 0 3 5 7 9 11
Figure 6.

A. 

Log_{10} CFU / Gram of Feces

Days Post-Infection

B. 

Log_{10} CFU / Gram of Feces

Days Post-Infection

C. 

Log_{10} Competitive Index

Days Post Infection

D. 

Log_{10} CFU / Gram of Feces

Days Post-Infection

E. 

Log_{10} Competitive Index

Days Post Infection

F. 

Log_{10} CFU / ml

Days Post Infection
Figure 7.

A. 

B. 

C. 

| Strain   | Infected/Uninfected Ratio | Co-housed (Days) | Treatment                  | # of Infected Contacts | Transmission Frequency (%) | p. value |
|----------|---------------------------|------------------|----------------------------|------------------------|---------------------------|----------|
| KPPRIS   | 4:1                       | 6-7              | None                       | 4/4                    | 100                       | -        |
| KPPRIS   | 4:1                       | 6-10             | Metabolic Cage             | 0/3                    | 0                         | 0.011    |
| KPPRIS   | 1:4                       | 6-7              | None                       | 5/16                   | -31                       | -        |
| KPPRIS   | 1:4                       | 6-7              | Abs Once (Index Only)      | 11/12                  | 92                        | 0.002    |
| KPNH1    | 1:4                       | 6-7              | Abs Daily (Cage)           | 12/12                  | 100                       | -        |
References

1. CDC. 2018. Healthcare-associated Infections. Centers for Disease Control.
2. Khan HA, Baig FK, Mehboob R. 2017. Nosocomial infections: Epidemiology, prevention, control and surveillance. Asian Pacific Journal of Tropical Biomedicine 7:478-482.
3. Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MA, Alvi RF, Aslam MA, Qamar MU, Salamat MKF, Baloch Z. 2018. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist 11:1645-1658.
4. Paczosa MK, Mecsas J. 2016. Klebsiella pneumoniae: Going on the Offense with a Strong Defense. Microbiol Mol Biol Rev 80:629-61.
5. Bergmans DCJJ, Bonten MJM, Gaillard CA, vanTiel FH, vanderGeest S, deLeeuw PW, Stobberingh EE. 1997. Indications for antibiotic use in ICU patients: a one-year prospective surveillance. Journal of Antimicrobial Chemotherapy 39:527-535.
6. Sakkas H, Bozidis P, Ilia A, Mpekoulis G, Papadopoulou C. 2019. Antimicrobial Resistance in Bacterial Pathogens and Detection of Carbapenemases in Klebsiella pneumoniae Isolates from Hospital Wastewater. Antibiotics (Basel) 8.
7. Broberg CA, Palacios M, Miller VL. 2014. Klebsiella: a long way to go towards understanding this enigmatic jet-setter. F1000Prime Rep 6:64.
8. Centers for Disease C, Prevention. 2013. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 62:165-70.
9. WHO. 2014. Antimicrobial resistance: global report on surveillance. World Health Organization, Geneva, Switzerland.
10. Shon AS, Bajwa RP, Russo TA. 2013. Hypervirulent (hypermucoviscous) Klebsiella pneumoniae: a new and dangerous breed. Virulence 4:107-18.
11. Rodriguez-Villar S, Fife A, Baldwin C, Warne RR. 2019. Antibiotic-resistant hypervirulent Klebsiella pneumoniae causing community-acquired liver abscess: an emerging disease. Oxf Med Case Reports 2019:omz032.
12. Liu C, Guo J. 2019. Hypervirulent Klebsiella pneumoniae (hypermucoviscous and aerobactin positive) infection over 6 years in the elderly in China: antimicrobial resistance patterns, molecular epidemiology and risk factor. Ann Clin Microbiol Antimicrob 18:4.
13. Fang CT, Lai SY, Yi WC, Hsuue PR, Liu KL, Chang SC. 2007. Klebsiella pneumoniae genotype K1: an emerging pathogen that causes septic ocular or central nervous system complications from pyogenic liver abscess. Clin Infect Dis 45:284-93.
14. Cheng NC, Yu YC, Tai HC, Hsueh PR, Chang SC, Lai SY, Yi WC, Fang CT. 2012. Recent trend of necrotizing fasciitis in Taiwan: focus on monomicrobial Klebsiella pneumoniae necrotizing fasciitis. Clin Infect Dis 55:930-9.
15. Han SH. 1995. Review of hepatic abscess from Klebsiella pneumoniae. An association with diabetes mellitus and septic endophthalmitis. West J Med 162:220-4.
16. Dao TT, Liebenthal D, Tran TK, Ngoc Thi Vu B, Ngoc Thi Nguyen D, Thi Tran HK, Thi Nguyen CK, Thi Vu HL, Fox A, Horby P, Van Nguyen K, Wertheim HF. 2014. Klebsiella pneumoniae oropharyngeal carriage in rural and urban Vietnam and the effect of alcohol consumption. PLoS One 9:e91999.
17. Fung CP, Lin YT, Lin JC, Chen TL, Yeh KM, Chang FY, Chuang HC, Wu HS, Tseng CP, Siu LK. 2012. Klebsiella pneumoniae in gastrointestinal tract and pyogenic liver abscess. Emerg Infect Dis 18:1322-5.
18. Viau RA, Hujer AM, Marshall SH, Perez F, Hujer KM, Briceno DF, Dul M, Jacobs MR, Grossberg R, Toltzis P, Bonomo RA. 2012. "Silent" dissemination of Klebsiella pneumoniae isolates bearing K. pneumoniae carbapenemase in a long-term care facility for children and young adults in Northeast Ohio. Clin Infect Dis 54:1314-21.

19. Gorrie CL, Mirceta M, Wick RR, Edwards DJ, Thomson NR, Strugnell RA, Pratt NF, Garlick JS, Watson KM, Pilcher DV, McGlooughlin SA, Spelman DW, Jenney AWJ, Holt KE. 2017. Gastrointestinal Carriage Is a Major Reservoir of Klebsiella pneumoniae Infection in Intensive Care Patients. Clinical Infectious Diseases 65:208-215.

20. Snitkin ES, Zelazny AM, Thomas PJ, Stock F, Group NCSP, Henderson DK, Palmore TN, Segre JA. 2012. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med 4:148ra116.

21. Selden R, Lee S, Wang WLL, Bennett JV, Eickhoff TC. 1971. Nosocomial Klebsiella Infections - Intestinal Colonization as a Reservoir. Annals of Internal Medicine 74:657+. 

22. Casewell M, Phillips I. 1977. Hands as Route of Transmission for Klebsiella Species. British Medical Journal 2:1315-1317.

23. Chiu CH, Su LH, Wu TL, Hung IJ. 2001. Liver abscess caused by Klebsiella pneumoniae in siblings. J Clin Microbiol 39:2351-3.

24. Harada S, Tateda K, Mitsui H, Hattori Y, Okubo M, Kimura S, Sekigawa K, Kobayashi K, Hashimoto N, Itoyama S, Nakai T, Suzuki T, Ishii Y, Yamaguchi K. 2011. Familial spread of a virulent clone of Klebsiella pneumoniae causing primary liver abscess. J Clin Microbiol 49:2354-6.

25. Lawley TD, Bouley DM, Hoy YE, Gerke C, Relman DA, Monack DM. 2008. Host transmission of Salmonella enterica serovar Typhimurium is controlled by virulence factors and indigenous intestinal microbiota. Infect Immun 76:403-16.

26. Lawley TD, Clare S, Walker AW, Goulding D, Stabler RA, Croucher N, Mastroeni P, Scott P, Raisen C, Mottram L, Fairweather NF, Wren BW, Parkhill J, Dougan G. 2009. Antibiotic treatment of clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect Immun 77:3661-9.

27. US Department of Health and Human Services N. 2015. Public Health Service policy on humane care and use of laboratory animals. US Department of Health and Human Services, NIH, Arlington, VA.

28. Tsai YK, Liou CH, Lin JC, Ma L, Fung CP, Chang FY, Siu LK. 2014. A suitable streptomycin-resistant mutant for constructing unmarked in-frame gene deletions using rpsL as a counter-selection marker. PLoS One 9:e109258.

29. Martin RM, Cao J, Brisse S, Passet V, Wu W, Zhao L, Malani PN, Rao K, Bachman MA. 2016. Molecular Epidemiology of Colonizing and Infecting Isolates of Klebsiella pneumoniae. mSphere 1.

30. Bachman MA, Breen P, Deornellas V, Mu Q, Zhao L, Wu W, Cavalcoti JD, Mobley HL. 2015. Genome-Wide Identification of Klebsiella pneumoniae Fitness Genes during Lung Infection. MBio 6:e00775.

31. Skorupski K, Taylor RK. 1996. Positive selection vectors for allelic exchange. Gene 169:47-52.

32. Simon R, Priefe U, Pühler A. 1983. A Broad Host Range Mobilization System for In Vivo Genetic Engineering: Transposon Mutagenesis in Gram Negative Bacteria. Bio/Technology 1:784-791.

33. Walker KA, Miner TA, Palacios M, Trzilova D, Frederick DR, Broberg CA, Sepulveda VE, Quinn JD, Miller VL. 2019. A Klebsiella pneumoniae Regulatory Mutant Has Reduced Capsule Expression but Retains Hypermucoviscosity. Mbio 10.

34. Struve C, Bojer M, Kroghfelt KA. 2008. Characterization of Klebsiella pneumoniae type 1 fimbriae by detection of phase variation during colonization and infection and impact on virulence. Infect Immun 76:4055-65.
35. Worlein JM, Baker K, Bloomsmith M, Coleman K, Koban TL. 2011. The Eighth Edition of the Guide for the Care and Use of Laboratory Animals (2011); Implications for Behavioral Management. American Journal of Primatology 73:98-98.

36. Ramage B, Erolin R, Held K, Gasper J, Weiss E, Brittnacher M, Gallagher L, Manoil C. 2017. Comprehensive Arrayed Transposon Mutant Library of Klebsiella pneumoniae Outbreak Strain KPN191. J Bacteriol 199.

37. Armbruster CE, Forsyth-DeOrnellas V, Johnson AO, Smith SN, Zhao L, Wu W, Mobley HLT. 2017. Genome-wide transposon mutagenesis of Proteus mirabilis: Essential genes, fitness factors for catheter-associated urinary tract infection, and the impact of polymicrobial infection on fitness requirements. PLoS Pathog 13:e1006434.

38. Nagpal R, Neth BJ, Wang S, Craft S, Yadav H. 2019. Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer’s disease markers in subjects with mild cognitive impairment. EBioMedicine 47:529-542.

39. Ahmadi S, Nagpal R, Wang S, Gagliano J, Kitzman DW, Soleimanian-Zad S, Sheikh-Zeinodddin M, Read R, Yadav H. 2019. Prebiotics from acorn and sago prevent high-fat-diet-induced insulin resistance via microbiome-gut-brain axis modulation. J Nutr Biochem 67:1-13.

40. Nagpal R, Newman TM, Wang S, Jain S, Lovato JF, Yadav H. 2018. Obesity-Linked Gut Microbiome Dysbiosis Associated with Derangements in Gut Permeability and Intestinal Cellular Homeostasis Independent of Diet. J Diabetes Res 2018:3462092.

41. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer N, Owens SM, Betley J, Fraser L, Bauer M, Gormley N, Gilbert JA, Smith G, Knight R. 2012. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J 6:1621-4.

42. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, Huttenhower C. 2011. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7:335-6.

43. Nagpal R, Shively CA, Appt SA, Register TC, Michalson KT, Vitolins MZ, Yadav H. 2018. Gut Microbiome Composition in Non-human Primates Consuming a Western or Mediterranean Diet. Front Nutr 5:28.

44. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. 2011. Metagenomic biomarker discovery and explanation. Genome Biol 12:R60.

45. Struve C, Krogfelt KA. 2003. Role of capsule in Klebsiella pneumoniae virulence: lack of correlation between in vitro and in vivo studies. FEMS Microbiol Lett 218:149-54.

46. Favre-Bonté S, Licht TR, Forestier C, Krogfelt KA. 1999. Klebsiella pneumoniae Capsule Expression Is Necessary for Colonization of Large Intestines of Streptomycin-Treated Mice. Infect Immun 67:6152-6156.

47. Perez F, Pultz MJ, Endimiani A, Bonomo RA, Donskey CJ. 2011. Effect of antibiotic treatment on establishment and elimination of intestinal colonization by KPC-producing Klebsiella pneumoniae in mice. Antimicrob Agents Chemother 55:2585-9.

48. Atarashi K, Suda W, Luo C, Kawaguchi T, Motoo I, Narushima S, Kiguchi Y, Yasuma K, Watanabe E, Tanoue T, Thaiss CA, Sato M, Toyooka K, Said HS, Yamagami H, Rice SA, Gevers D, Johnson RC, Segre JA, Chen K, Kolls JK, Elinav E, Morita H, Xavier RJ, Hattori M, Honda K. 2017. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. Science 358:359-365.

49. Ma LC, Fang CT, Lee CZ, Shun CT, Wang JT. 2005. Genomic heterogeneity in Klebsiella pneumoniae strains is associated with primary pyogenic liver abscess and metastatic infection. J Infect Dis 192:117-28.
50. Bobo LD, Dubberke ER. 2010. Recognition and prevention of hospital-associated enteric infections in the intensive care unit. Crit Care Med 38:5324-34.
51. Aitken C, Jeffries DJ. 2001. Nosocomial spread of viral disease. Clin Microbiol Rev 14:528-46.
52. Chase-Topping M, Gally D, Low C, Matthews L, Woolhouse M. 2008. Super-shedding and the link between human infection and livestock carriage of Escherichia coli O157. Nat Rev Microbiol 6:904-12.
53. Walker KA, Treat LP, Miller VL. 2020. The small protein RmpD drives hypermucoviscosity in Klebsiella pneumoniae. doi:10.1101/2020.01.08.899096.
54. Tytgat HLP, Nobrega FL, van der Oost J, de Vos WM. 2019. Bowel Biofilms: Tipping Points between a Healthy and Compromised Gut? Trends Microbiol 27:17-25.
55. Krogsfelt KA, Bergmans H, Klemm P. 1990. Direct evidence that the FimH protein is the mannose-specific adhesin of Escherichia coli type 1 fimbriae. Infect Immun 58:1995-1998.
56. Lau HY, Huffnagle GB, Moore TA. 2008. Host and microbiota factors that control Klebsiella pneumoniae mucosal colonization in mice. Microbes Infect 10:1283-90.
57. Sequeira RP, McDonald JAK, Marchesi JR, Clarke TB. 2020. Commensal Bacteroidetes protect against Klebsiella pneumoniae colonization and transmission through IL-36 signalling. Nature Microbiology doi:10.1038/s41564-019-0640-1.
58. Jung HJ, Litmann ER, Seok R, Leiner IM, Taur Y, Peled J, van den Brink M, Ling L, Chen L, Kreiswirth BN, Goodman AL, Pamer EG. 2019. Genome-Wide Screening for Enteric Colonization Factors in Carabapenem-Resistant ST258 Klebsiella pneumoniae. MBio 10.
59. Kaur CP, Vadivelu J, Chandramathi S. 2018. Impact of Klebsiella pneumoniae in lower gastrointestinal tract diseases. J Dig Dis 19:262-271.
60. Tan YH, Chen Y, Chu WHW, Sham LT, Gan YH. 2020. Cell envelope defects of different capsule-null mutants in K1 hypervirulent Klebsiella pneumoniae can affect bacterial pathogenesis. Mol Microbiol 113:889-905.
61. Diago-Navarro E, Calatayud-Basolga I, Sun D, Khairallah C, Mann I, Ulacia-Hernando A, Sheridan B, Shi M, Fries BC. 2017. Antibody-Based Immunotherapy To Treat and Prevent Infection with Hypervirulent Klebsiella pneumoniae. Clin Vaccine Immunol 24.
62. Lawlor MS, Handley SA, Miller VL. 2006. Comparison of the host responses to wild-type and cpsB mutant Klebsiella pneumoniae infections. Infect Immun 74:5402-7.
63. Moranta D, Regueiro V, March C, Llobet E, Margareto J, Larrarte E, Garmendia J, Bengoechea JA. 2010. Klebsiella pneumoniae capsule polysaccharide impedes the expression of beta-defensins by airway epithelial cells. Infect Immun 78:1135-46.
64. Russell CW, Fleming BA, Jost CA, Tran A, Stenquist AT, Wambaugh MA, Bronner MP, Mulvey MA. 2018. Context-Dependent Requirements for FimH and Other Canonical Virulence Factors in Gut Colonization by Extraintestinal Pathogenic Escherichia coli. Infect Immun 86.
65. Edwards RA, Puente JL. 1998. Fimbrial expression in enteric bacteria: a critical step in intestinal pathogenesis. Trends Microbiol 6:282-7.
66. Chung DR, Lee H, Park MH, Jung SI, Chang HH, Kim YS, Son JS, Moon C, Kwon KT, Ryu SY, Shin SY, Ko KS, Kang CI, Peck KR, Song JH. 2012. Fecal carriage of serotype K1 Klebsiella pneumoniae ST23 strains closely related to liver abscess isolates in Koreans living in Korea. Eur J Clin Microbiol Infect Dis 31:481-6.
67. Woolhouse ME, Dye C, Etard JF, Smith T, Charlwood JD, Garnett GP, Hagan P, Hii JL, Ndhlouvu PD, Quinnell RJ, Watts CH, Chandiwa SK, Anderson RM. 1997. Heterogeneities in the transmission of infectious agents: implications for the design of control programs. Proc Natl Acad Sci U S A 94:338-42.
68. Lawlor MS, Hsu J, Rick PD, Miller VL. 2005. Identification of Klebsiella pneumoniae virulence determinants using an intranasal infection model. Molecular Microbiology 58:1054-1073.
69. Palacios M, Broberg CA, Walker KA, Miller VL. 2017. A Serendipitous Mutation Reveals the Severe Virulence Defect of a Klebsiella pneumoniae fepB Mutant. mSphere 2.

70. Pomakova DK, Hsiao CB, Beanan JM, Olson R, MacDonald U, Keynan Y, Russo TA. 2012. Clinical and phenotypic differences between classic and hypervirulent Klebsiella pneumonia: an emerging and under-recognized pathogenic variant. European Journal of Clinical Microbiology & Infectious Diseases 31:981-989.

71. Agard MJ, Ozer EA, Morris AR, Piseaux R, Hauser AR. 2019. A Genomic Approach To Identify Klebsiella pneumoniae and Acinetobacter baumannii Strains with Enhanced Competitive Fitness in the Lungs during Multistrain Pneumonia. Infect Immun 87.